ABEO - Abeona Therapeutics Inc.
| Previous Close | 2.5400 |
| Open | 2.5700 |
| Bid | 2.5400 x 2200 |
| Ask | 2.5700 x 900 |
| Day's Range | 2.5200 - 2.6000 |
| 52 Week Range | 1.4600 - 8.4100 |
| Volume | 1,360,619 |
| Avg. Volume | 1,320,422 |
| Market Cap | 212.185M |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5900 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.33 |
- GlobeNewswire
Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) capsids generated using the University of North Carolina’s (UNC) AIM™ vector platform and that the USPTO allowed the claims of a companion patent application, which will issue in the next several weeks. Both patents are exclusively licensed by the Company from UNC. On January 14, 2020, the USPTO issued UNC’s U.S. Patent No. 10,532,110, entitled “AAV Vectors Targeted to the Central Nervous System.” The patent provides protection for methods of delivering Abeona’s AAV204-based gene therapy vectors to the central nervous system until November 2036.
- GlobeNewswire
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has received Institutional Review Board (IRB) approval from Stanford University to commence the VIITAL™ study, the Company’s pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The majority of patients targeted for enrollment have completed the pre-screening process at Stanford, and the Company expects the first patient in the VIITAL™ study to be treated in the first quarter of 2020. “We expect 2020 to be a transformational year at Abeona, and we are proud to start it with the initiation of our pivotal Phase 3 study evaluating EB-101 in RDEB,” said João Siffert, M.D., Chief Executive Officer.
- Business Wire
THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc.
- ACCESSWIRE
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- ACCESSWIRE
DEADLINE ALERT - Abeona Therapeutics Inc. (ABEO) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: January 2, 2019
NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or "the ...
- Simply Wall St.
Insider Buying: The Abeona Therapeutics Inc. (NASDAQ:ABEO) Just Bought US$500k Worth Of Shares
Investors who take an interest in Abeona Therapeutics Inc. (NASDAQ:ABEO) should definitely note that insider Stefano...
- ACCESSWIRE
THURSDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- GlobeNewswire
ABEONA EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Thursday Deadline in Securities Class Action - ABEO
NEW YORK, Dec. 31, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31,.
- ACCESSWIRE
6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- Business Wire
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Abeona Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Abeona Therapeutics, Inc. (NASDAQ: ABEO) securities between May 31, 2018 and September 23, 2019 (the "Class Period"). Investors have until January 2, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 23, 2019 / The Schall Law Firm ,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. ("Abeona" ...
- GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Deadline in Securities Class Action – ABEO
NEW YORK, Dec. 24, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31,.
- GlobeNewswire
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten public offering, with a gross offering size of approximately $103.5 million, which includes the full exercise of the underwriters’ option to purchase 5,400,000 additional shares of common stock, at a public offering price of $2.50 per share. In addition, as part of the offering, Abeona sold to Great Point Partners (“GPP”), an existing investor, pre-funded warrants to purchase up to an aggregate of 9,017,055 shares of common stock at a purchase price of $2.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
- ACCESSWIRE
FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 20, 2019 / The Schall Law Firm ,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. ("Abeona" ...
- GlobeNewswire
Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to the Company’s ABO-102 program studying its adeno-associated virus 9 (AAV9) gene therapy for Sanfilippo syndrome type A (MPS IIIA). The PRIME designation is based on nonclinical data and clinical data from the Transpher A Study, a global Phase 1/2 clinical trial evaluating a single-dose of ABO-102 for the treatment of children with MPS IIIA.
- Zacks
Are Options Traders Betting On A Big Move In Abeona Therapeutics (ABEO) Stock?
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
- GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO), AZZ, Inc. (AZZ) & Twitter, Inc. (TWTR)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
- GlobeNewswire
Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public offering of 26,982,945 shares of its common stock at a public offering price of $2.50 per share and in lieu of common stock, pre-funded warrants to purchase 9,017,055 shares of its common stock at a purchase price of $2.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. All of the shares of common stock and pre-funded warrants are being offered by Abeona.
- GlobeNewswire
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its common stock, and pre-funded warrants in lieu of common stock, in an underwritten public offering pursuant to an existing shelf registration statement. All of the securities in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- ACCESSWIRE
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- Newsfile
Abeona Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Abeona Therapeutics Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - December 19, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) ("Abeona" or the "Company") of the December 31, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Abeona stock or options between May 31, ...
- GlobeNewswire
ABEO NOTICE: Pawar Law Group Reminds Investors of JANUARY 2 Deadline in Securities Class Action Lawsuit Against Abeona Therapeutics Inc.– ABEO
Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Abeona Therapeutics Inc. (ABEO) from May 31, 2018 through September 23, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abeona Therapeutics Inc. investors under the federal securities laws. A class action lawsuit has already been filed.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ABEO
Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-10181, is on behalf of a class consisting of investors who purchased or otherwise acquired Abeona securities between May 31, 2018 and September 23, 2019, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE
SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO), AZZ, Inc. (AZZ) & Twitter, Inc. (TWTR)
NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...
